Zu "K06619" wurden 170 Artikel gefunden!
Für die Filterung wurden keine Ergebnisse gefunden!
Abl Substrate Peptide (trifluoroacetate salt)
Artikelnummer: Cay36969-1
Abl substrate peptide is a peptide substrate for the tyrosine kinase Abl. It is selectively phosphorylated by Abl over c-Src kinase at 20 µM. Abl substrate peptide has been used to quantify Abl kinase activity in vitro.Formal Name:...
| Schlagworte: | L-alpha-glutamyl-L-alanyl-L-isoleucyl-L-tyrosyl-L-alanyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-lysyl-L-lysyl-L-lysin... |
| Anwendung: | Tyrosine kinase Abl peptide substrate |
| MW: | 1336.6 D |
ab 104,00 €
Anti-c-Abl
Artikelnummer: ELK-EA355.100
c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. It is implicated in regulating cell proliferation, apoptosis, differentiation, cell adhesion, and stress responses. Protein function: Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and...
| Schlagworte: | Anti-ABL, Anti-ABL1, Anti-p150, Anti-Proto-oncogene c-Abl, Anti-Tyrosine-protein kinase ABL1, Anti-Abelson... |
| Anwendung: | IHC |
| Wirt: | Rabbit |
| Spezies-Reaktivität: | human |
283,00 €
Dasatinib
Artikelnummer: Cay11498-10
Dasatinib is a potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family. It is effective at sub-nanomolar concentrations, inhibiting Src, Abl, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively. At nanomolar concentrations, dasatinib also blocks the...
| Schlagworte: | BMS 354825, Sprycel,... |
| Anwendung: | Tyrosine kinase inhibitor |
| CAS | 302962-49-8 |
| MW: | 488 D |
ab 43,00 €
Saracatinib
Artikelnummer: Cay11497-5
Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases. Saracatinib is orally available and blocks cell motility, migration, adhesion,...
| Schlagworte: | AZD 0530,... |
| Anwendung: | c-Src / Abl inhibitor |
| CAS | 379231-04-6 |
| MW: | 542 D |
ab 42,00 €
Dasatinib, Free Base (Sprycel, BMS-354825, CAS...
Artikelnummer: LC-D-3307_5g
Soluble in DMSO at 200 mg/mL, very poorly soluble in ethanol, very poorly soluble in water, maximum solubility in plain water is estimated to be about 10 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility
| Schlagworte: | BMS 354825, Sprycel,... |
| Anwendung: | Tyrosine kinase inhibitor |
| CAS | 302962-49-8 |
| MW: | 488,01 D |
ab 83,00 €
Bosutinib
Artikelnummer: Cay12030-10
Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively). It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others. Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to...
| Schlagworte: | SKI 606, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile |
| Anwendung: | c-Src and Abl inhibitor |
| CAS | 380843-75-4 |
| MW: | 530.5 D |
ab 60,00 €
Abl Kinase, active human recombinant protein
Artikelnummer: BPS-40411
Active human Abelson murine leukemia viral oncogene homolog 1 (Abl-1) (GenBank Accession No. NM_007313), amino acids 248-531, with N-terminal His-tag, MW = 33 kDa, expressed in a Baculovirus-infected Sf9 cell expression system.
| Schlagworte: | ABL, p150, ABL1, Proto-oncogene c-Abl, Tyrosine-protein kinase ABL1, Abelson tyrosine-protein kinase 1, Abelson murine... |
| Anwendung: | Enzyme kinetics, inhibitor screening, profiling |
| MW: | 33 kD |
555,00 €
GZD-824
Artikelnummer: Cay21508-1
GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells...
| Schlagworte: | 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-be... |
| Anwendung: | Bcr/Abl tyrosine kinase mutant inhibitor |
| CAS | 1257628-77-5 |
| MW: | 532.6 D |
ab 43,00 €
Asciminib
Artikelnummer: Cay26126-1
Asciminib is an allosteric inhibitor of Abl1 (IC50 = 0.45 nM). It is selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 µM), as well as ion channels, nuclear receptors, G protein-coupled receptors (GPCRs), and transporters. Asciminib inhibits the proliferation of Luc-Ba/F3 cells...
| Schlagworte: | ABL001, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-3-pyridinecarboxamide |
| Anwendung: | Allosteric Abl1 inhibitor |
| CAS | 1492952-76-7 |
| MW: | 449.8 D |
ab 84,00 €
Bafetinib
Artikelnummer: Cay19169-5
Bcr-Abl, a fusion protein with deregulated tyrosine kinase activity, is highly expressed in chronic myelogenous leukemia (CML). Bafetinib is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib (Cay-13139), with modifications added to improve binding and potency against...
| Schlagworte: | INNO-406, NS-187,... |
| Anwendung: | Bcr-Abl tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor |
| CAS | 859212-16-1 |
| MW: | 576.6 D |
ab 60,00 €
Rebastinib
Artikelnummer: Cay21465-1
Rebastinib is an orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM) as well as the gatekeeper mutant Abl1T315I (IC50 = 4 nM) and the activation loop mutant Abl1H396P. It also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar...
| Schlagworte: | DCC-2036,... |
| Anwendung: | ABL1 inhibitor |
| CAS | 1020172-07-9 |
| MW: | 553.6 D |
ab 64,00 €
PD 166326
Artikelnummer: Cay9000988-10
PD 166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC50 = 8 nM) and Bcr/Abl-dependent cell growth (IC50 = 0.4 nM). In addition to targeting a select group of receptor tyrosine kinases, PD 166326 also potently inhibits c-src (IC50 = 6 nM). Orally administered PD 166326 is...
| Schlagworte: | 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one |
| Anwendung: | Receptor tyrosine kinase inhibitor |
| CAS | 185039-91-2 |
| MW: | 427.3 D |
ab 131,00 €